Section of Immunoallergology, Department of Internal Medicine, Center of Research, Transfer and High Education DENOTHE, University of Florence, Florence, Italy.
Curr Opin Allergy Clin Immunol. 2012 Feb;12(1):1-6. doi: 10.1097/ACI.0b013e32834ecc9a.
Allergen-specific immunotherapy is the only specific, dose-dependent and time-dependent and disease-modifying strategy for the treatment of allergy associated with clinical improvement and biological tolerance which may persist years after discontinuation.
Successful immunotherapy in respiratory allergy is associated with the immunodeviation of Th2 response to a more protective allergen-specific Th1 cells and with the induction of interleukin-10 (IL-10)/transforming growth factor (TGF)-β-producing T regulatory cells in blood and inflamed airways. Subcutaneous treatment and sublingual treatments induce similar alterations which are dose-dependent and time-dependent.
This study provides an update on the immunological T-cell responses during subcutanous immunotherapy and sublingual immunotherapy, giving a unifying view of the redirecting mechanisms and regulating mechanisms elicited by these treatments.
变应原特异性免疫治疗是治疗过敏的唯一特异性、剂量依赖性、时间依赖性和疾病修饰治疗策略，可改善临床症状并产生生物学缓解，停药后数年仍可持续。
呼吸道变应性疾病的免疫治疗成功与 Th2 反应向更具保护性的变应原特异性 Th1 细胞的免疫偏移有关，并与诱导白细胞介素-10（IL-10）/转化生长因子（TGF）-β产生的 T 调节细胞有关在血液和炎症气道中。皮下治疗和舌下治疗诱导相似的改变，这些改变是剂量依赖性和时间依赖性的。
本研究综述了皮下免疫治疗和舌下免疫治疗期间 T 细胞免疫应答的最新进展，为这些治疗方法引起的重定向机制和调节机制提供了统一的观点。
